State of New Jersey Common Pension Fund D Invests $2.26 Million in Mirum Pharmaceuticals, Inc. $MIRM

State of New Jersey Common Pension Fund D acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 30,800 shares of the company’s stock, valued at approximately $2,258,000. State of New Jersey Common Pension Fund D owned approximately 0.06% of Mirum Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Emerald Advisers LLC lifted its position in shares of Mirum Pharmaceuticals by 20.9% in the 3rd quarter. Emerald Advisers LLC now owns 369,600 shares of the company’s stock worth $27,095,000 after purchasing an additional 63,834 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in Mirum Pharmaceuticals during the third quarter valued at approximately $808,000. Candriam S.C.A. raised its stake in Mirum Pharmaceuticals by 8.0% in the third quarter. Candriam S.C.A. now owns 403,026 shares of the company’s stock worth $29,546,000 after buying an additional 30,021 shares in the last quarter. Baader Bank Aktiengesellschaft bought a new stake in Mirum Pharmaceuticals during the 3rd quarter valued at $503,000. Finally, TimesSquare Capital Management LLC purchased a new position in shares of Mirum Pharmaceuticals in the 3rd quarter valued at $22,041,000.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Raymond James Financial restated a “strong-buy” rating and set a $110.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. Stifel Nicolaus increased their price target on shares of Mirum Pharmaceuticals from $92.00 to $98.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Evercore reaffirmed an “outperform” rating and issued a $101.00 price objective on shares of Mirum Pharmaceuticals in a research report on Tuesday, January 20th. Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. Finally, Leerink Partners set a $100.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $110.17.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 2,631 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total transaction of $271,782.30. Following the sale, the chief operating officer directly owned 20,655 shares of the company’s stock, valued at $2,133,661.50. The trade was a 11.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Patrick J. Heron bought 131,425 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Friday, January 23rd. The stock was purchased at an average price of $68.48 per share, with a total value of $8,999,984.00. Following the purchase, the director directly owned 459,010 shares in the company, valued at $31,433,004.80. The trade was a 40.12% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders sold 45,136 shares of company stock valued at $4,352,029. Company insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock opened at $105.16 on Monday. The company has a 50 day moving average price of $90.24 and a 200 day moving average price of $77.94. The firm has a market capitalization of $5.40 billion, a P/E ratio of -122.28 and a beta of 0.49. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals, Inc. has a 52 week low of $36.88 and a 52 week high of $107.41.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.